高强度聚焦超声联合吉西他滨治疗胰腺癌26例临床分析.docVIP

高强度聚焦超声联合吉西他滨治疗胰腺癌26例临床分析 　　作者：黄正春，李军成△，田 斌，吴 斌 作者单位：215000 江苏苏州，苏州大学第二附属医院普外科(△通讯作者) 　　【摘要】 目的 探讨高强聚焦超声( HIFU) 热疗联合吉西他滨化疗对晚期胰腺癌患者的疗效、安全性及对肿瘤标志物(CA19-9、CEA)的影响。方法 26例晚期胰腺癌患者采用HIFU联合吉西他滨治疗，治疗前、后分别空腹检测消化道癌相关抗原(CA19-9)和癌胚抗原(CEA)浓度。结果 26例晚期胰腺癌患者中共19 例临床受益(CBR)，CBR率达73%;治疗后CA19-9、CEA浓度较治疗前下降明显;中位生存期8.5个月;在治疗过程中无明显不良反应。结论 HIFU 热疗联合吉西他滨化疗能有效控制肿瘤进展,改善生活质量,延长生存期，对肿瘤标志物CA19-9、CEA有明显下调作用,无明显不良反应。 　　【关键词】 高强度聚焦超声;吉西他滨;胰腺癌 　　High intensity focused ultrasound combined with Gemcitabine in 26 patients with pancreatic carcinoma 　　HUANG Zheng-chun，LI Jun-cheng,TIAN Bin,et al.Department of General Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215000, China 　　[Abstract] Objective To investigate the therapeutic effect，safety and the effect of two tumormarkers of high intensity focused ultrasound ( HIFU) combined with Gemcitabine in treating pancreatic carcinoma.Methods The 26 patients suffering from pancreatic carcinoma accepted the treatment of HIFU combined with Gemcitabine . Detected the carbohydrate antigen 19-9(CA19-9)，carcino embryonic antigen (CEA)of every patients before and after the treatment.Results There were 19 clinical benefit response among 26 pancreatic carcinoma patients received the treatment. The clinical benefit response rate was 73%. The descent of CA19-9，CEA was significant after the treatment .The median time of survival were 8.5 months. The complicated symptoms did not perform after the treatment.Conclusion HIFU combined with Gemcitabine in treating pancreatic carcinoma can control the progress of tumor，improve the quality of life，and prolong overall survival. It also can reduce the levels of CA19-9 and CEA. Furthermore，no significant adverse reaction occurrences in the treatment. 　　[Key words] high intensity focused ultrasound;Gemcitabine;pancreatic carcinoma 　　胰腺癌是常见的消化道恶性肿瘤之一,发病率在世界范围内呈逐年上升趋势,占恶性肿瘤死因的第4 位[1]。确诊时80%以上患者已属晚期，手术切除率低,中位生存期仅3～6个月[2]。本院2007年1月-2010年1月采用HIFU联合吉西他滨治疗晚期胰腺癌26例，疗效确切，现报告如下。 　　1 资料与方